Facility Information
CRANBURY, NEW JERSEY
WORLDWIDE MEDICINES
Facility Highlights
The Cranbury Distribution Center distributes domestic and international products for the Worldwide Medicines Group
CSO as well as Bracco Diagnostics, and NovoNordisk.
The facility is one of two domestic distribution facilities servicing the US and international marketplace with the other
located in Mt. Vernon, IN. It is part of the North American Logistics group which is headquartered in Cranbury, N.J.
t this location are the US Customer Service, Global Transportation and Regulatory Compliance & EHS functions
Economic / Social Sustainability
BRISTOL MYERS SQUIBB RESEARCH
Groundbreaking Research Reveals That One in Four Type
II Diabetes Patients Have Heart Disease But Show No
Symptoms
American Society of Nuclear Cardiology Late-Breaking Clinical Data
Presented Sunday, September 29, 8:30 - 10:00 am; - Early Findings
Demonstrate Cardiac Imaging with Cardiolite(R) Identifies 'Silent' Heart
Disease Early in Patients with Diabetes, Potentially Saving Many from
Premature Heart Attack or Death Monday September 30, 9:48 am ET
BALTIMORE, Md., Sept. 30 /PRNewswire/ -- The preliminary results of a groundbreaking study show
that non-invasive imaging with Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for
Injection) can identify "silent" coronary artery disease (CAD) at an early stage in diabetes patients -- a
high-risk population who often do not exhibit any apparent symptoms of heart disease. If confirmed,
these research findings, presented yesterday at the Annual Scientific Session of the American Society
of Nuclear Cardiology (ASNC), could pave the way for evidence-based guidelines for selectively
screening these at-risk patients, potentially allowing for earlier intervention and saving many from
premature heart attack or death. Heart
disease is the leading cause of death for
the nearly 16 million Americans with type II diabetes -- whose risk is
two to four times that of the general population. Identifying coronary artery
disease in these patients is difficult because many have no apparent "chest pain" symptoms. As a
result, this so-called silent ischemia may go undiagnosed until symptoms of late-stage heart disease
occur, including heart attack and cardiac death.
"These preliminary results are very important because recent studies have shown that patients with
diabetes are still not fully aware of their risk for heart disease despite the fact that it is their leading
cause of reduced life expectancy," said Frans J. Th. Wackers, M.D., professor of medicine, Yale
University School of Medicine, who designed the study. "If these findings are confirmed, selectively
screening these patients early with Cardiolite can help identify CAD in patients with no outward
symptoms, potentially protecting many from more severe coronary events."
The study -- Detection of Ischemia in Asymptomatic Diabetics (DIAD) -- is the first multi center study to
detect "silent" ischemia (heart disease) in patients with diabetes. Today's preliminary analysis of 522
patients represents initial results of this two-year study. In this data set, twenty- six percent of patients
had an abnormal Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) test
suggesting "silent" CAD. Of those exhibiting an abnormal finding, 83 percent (114 patients) were found
to have abnormal blood flow, while the remaining 17 percent (23 patients) were found to have other
abnormal findings such as depressed left ventricular ejection fraction, another measure of heart health.
These results were made more remarkable by the absence of CAD symptoms in all patients tested.
"As the doctors who see patients with diabetes every day, we know that many don't display the classic
symptoms of heart disease, making it difficult to detect ischemia before the onset of advanced and
symptomatic disease," said Paul S. Jellinger, MD, former president of the American Association of
Clinical Endocrinologists. "Given this significant diagnostic challenge and the disproportionate threat
CAD poses to this patient population, identifying tests that assist in detecting heart disease at an early
stage are critical. Needless to say, today's results are an encouraging first step."
The prospective study involves more than 1,000 patients with type II diabetes aged 50 to 75 years with
no known coronary artery disease. Enrolled patients were randomized to receive Cardiolite, the
leading stress myocardial perfusion imaging (stress MPI) agent, and five year follow-up, or follow-up
alone. Prior studies have shown Cardiolite to be an accurate predictor of major cardiac events in
patients with diabetes known to have heart disease.
Stress MPI is a nuclear cardiology procedure that uses a radiopharmaceutical, such as Cardiolite, to
measure blood flow to various structures of the heart. Patients undergo a Cardiolite study both to
diagnose heart disease as well as to assess their risk for a future cardiac event. In patients with known
or suspected coronary artery disease, a normal stress Cardiolite study is associated with a less than
one percent chance that the patient will experience a hard cardiac event (death or myocardial
infarction) in the next 12 months.
Bristol-Myers Squibb Medical Imaging, Inc., the makers of Cardiolite, has provided more than $2
million in a research grant to Yale University School of Medicine for the two-year study. The company
also supplies product and technical support. Fujisawa Healthcare, Inc. also provides funding for the
trial.
"Our company is proud of its leadership role as both an innovator in the area of cardiovascular imaging
and therapies for the management of type II diabetes," said Peter Gardiner, MD, vice president,
Medical Sciences, Bristol- Myers Squibb Medical Imaging, Inc. "Our support of the DIAD study is just
one example of our strong commitment to enhancing and extending patients' lives through important
clinical research designed to optimize the management of cardiac patients."
Yale University School of Medicine serves as the study's lead investigation site. The other investigative
sites are: University of Alabama, Birmingham, AL; Cardiology Consultants, Calgary, Alberta, Canada;
University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Virginia, Charlottesville, VA;
Midwest Cardiology, Columbus, OH; Hartford Hospital, Hartford, CT; Kansas City Cardiology
Associates, Kansas City, MO; University of Montreal, Montreal, QUE, Canada; Tulane University, New
Orleans, LA; Soundview Research Associates, Norwalk, CT; Maine Cardiology Associates, Portland,
ME; University of Rochester, Rochester, NY; Medstar Clinical Research Center, Washington, DC.
Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) is the leading cardiac
stress imaging agent in the United States. It is the only heart imaging agent that is FDA-approved to
both non-invasively evaluate the heart's pumping ability (function) and gauge the amount of blood flow
to the heart muscle itself (perfusion) -- and thus is used to quickly assess whether a patient has
already had a heart attack or is at risk for one in the future. Cardiolite is also the only technetium agent
in the U.S. approved for acquiring diagnostic information for use in patient management decisions.
Exercise and pharmacologic stress testing should be performed only under the supervision of a
qualified physician. Cardiolite has been rarely associated with acute severe allergic events of
angioedema and uticaria. The most frequently reported adverse events include headache, chest
pain/angina, ST segment changes on ECG, nausea and abnormal taste and smell.
Bristol-Myers Squibb Medical Imaging, Inc. is a worldwide leader in cardiovascular imaging whose
mission is to extend and enhance human life by offering innovative approaches to see deeper into the
heart and vasculature. Bristol-Myers Squibb Medical Imaging, Inc. is a wholly-owned subsidiary of
Bristol-Myers Squibb Company (NYSE: BMY - News), a $19 billion pharmaceutical and related health
care products company.
Cardiolite is a registered trademark of Bristol-Myers Squibb Medical Imaging, Inc.
ENGINEERING 9
Strategic Planning - Competition 1
Who are the competitors?
?
?
?
?
?
Existing Firms
New Entrants
Substitute Products
Suppliers
Customers
What are the strategies
?
?
?
?
Overall Cost Leadership
Product Differentiation
Focus on Market Segment
Don't be "Stuck in the Middle"
How To Analyze Competitors
Look at:
?
?
?
?
Goals
Risk Adversity
Capabilities
In general, collect information, and be alert for signals.
What competitive moves are possible?
?
?
?
?
?
1
Commitment
Evolution of product or marketing
Vertical Integration
Capacity Expansion
Enter New Business
Michael Porter, Competitive Strategies - Techniques for Analyzing Industries and Competition Free Press,
New York 1980.
COMPETITIVE ADVANTAGE2
1.
INDUSTRY STRUCTURAL ADVANTAGES
a. level of competition
b. loyalty of customer
c. ease of switching products
d. profit margins
e. product protection, ie. patents.
2.
3.
Compare Pharmaceuticals versus Airlines
How does a firm create competitive advantage?
? What does it do that is unique and valuable and can’t
really be replaced exactly by others?
? What is its added value?
4.
How does a firm create added value?-an examination of its
activities.
CONCERNS: Creating versus Sustaining Value:
What in the structure of the value allows it to remain over
time?
a. neutralize unattractive features of industry
b. capitalize on good features
c. examine how a leader might restructure the industry
without diminishing their advantage
? Customer willingness to pay is symmetrical to Supplier’s
willingness to accept. This means that value can be
achieved both from downstream customers and execution
of activities
? Competitive advantage derives essentially from lack of
alternatives on the purchasers behalf. In other words,
scarcity.
? Value derives when difference in willingness to pay is
incrementally higher than increase in cost of production.
VALUE CHAIN
2
Based on the article “Creating competitive advantage” by P.Ghemawat and J. Rivkin
? Design, produce, sell, deliver and service activities incur
and thus define costs as well as value for which a
customer will pay.
? Analysis by activity can determine where a company does
not perform efficiently. Value chain is used to do the
analysis.
? Primary Activities: inbound logistics, operations, outbound
logistics; marketing sales and after sale service.
? Support Activities: inputs, technology and human
resources, firm infrastructure.
? Determine willingness to pay relative to competition
The Novo Group is a family of independent companies with a
common history and shared values. All Novo Group companies
share and benefit from the governance principles stated in the
Novo Group Charter, including the Novo Way of Management.
The Novo Nordisk Foundation A profit-making foundation. It
provides a stable basis for Novo Group’s business and research
activities. Novo A/S, the Foundation owns all A shares in Novo
Nordisk A/S and Novozymes A/S. Supports scientific, medical
humanitarian and social causes, other Danish research.
Novo A/S is an investment and holding company owned 100%
by the Novo Nordisk Foundation with the purpose of managing
the Novo Nordisk Foundation's funds and investment in
companies inside and outside the bioindustrial and
biopharmaceutical area. In addition, Novo A/S drives and
monitors the implementation of The Novo Way of Management
in Novo Group companies.
Novo Nordisk A/S is a global niche pharmaceutical company
with biotechnology expertise. In diabetes care, Novo Nordisk
has the leading position worldwide, both in terms of research
and development pipeline, product range and geographical
coverage. With the introduction of NovoSeven ®, a unique
preparation for the treatment of haemophiliacs who do not
respond to coagulation factor replacement therapy due to
antibody formation, Novo Nordisk has added a new growth area.
In addition, Novo Nordisk produces and markets leading
products for growth disorders and hormone replacement
therapy.
Novozymes A/S biology-based world leader in enzymes. The
company is the market leader in its field – developing, producing and
selling enzymes for industrial use to the three market segments:
technical, food and animal feed. Novozymes has pioneered virtually
all new product developments in the industry and remains at the
forefront of the enzyme market development, using a fully integrated,
proprietary biotechnology platform for the discovery and delivery of
enzyme products.
Company characteristics in the Novo
Group
Present as well as future companies in the Novo Group must demonstrate willingness, ability and resolve to
meet the following six criteria:
?
Company products and services make a significant difference in improving the way people live and
work.
?
The company is perceived to be the innovator - in technology, in products, in services and/or in market
approach.
?
Company activities, practices and deliverables are perceived to be economically viable, environmentally
sound and socially fair.
?
?
?
The company is among the best in its business and a challenging place to work.
Living the Novo values and business conduct principles as defined in the Novo Way of Management.
Delivering competitive financial performance.
Values
Accountable
Each of us shall be accountable - to the company, ourselves and society - for the quality
of our efforts, for contributing to our goals and for developing our culture and shared
values.
Ambitious
We shall set the highest standard in everything we do and reach challenging goals.
Responsible
We shall conduct our business in a socially and environmentally responsible way and
contribute to the enrichment of the communities in which we operate.
Engaged with stakeholders
We shall seek an active dialogue with our stakeholders to help us develop and strengthen
our businesses.
Open and honest
Our business practices shall be open and honest to protect the integrity of the Novo
Group companies and of each employee.
Ready for change
We must foresee change and use it to our advantage. Innovation is key to our business
and therefore we will encourage a learning culture for the continuous development and
improved employability of our people.
Commitments
Financial responsibility
We will work to continuously improve our financial performance by setting high objectives
for growth and value creation and deliver competitive performance in these areas. We will
maintain an open dialogue with our stakeholders and comply with international reporting
standards.
Environmental responsibility
We will work to continuously improve our environmental performance by setting high
objectives and integrating environmental and bioethical considerations into our daily
business. We will maintain an open dialogue with our stakeholders and report annually on
our environmental performance.
?
We subscribe to the International Chamber of Commerce's Charter for Sustainable
Development
?
We support the United Nations Convention on Biological Diversity.
Social responsibility
We will work to continuously improve our social performance by setting high objectives
and integrating social, human rights and health & safety considerations into our daily
business. We will maintain an open dialogue with our stakeholders and report annually on
our social performance.
?
We support the United Nations Universal Declaration of Human Rights
NOVO NORDISK CURRENT ORGANIZATIONAL SETUP
The Novo Group